




BEST AVAILABLE COPY

GP 1614  
#4

Patent Docket P1760R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of David B. Agus et al. Serial No.: 09/602,800 Filed: June 23, 2000 For: TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES	Group Art Unit: 1614 Examiner: To be determined   
---	--

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

- (a) ☐ accompanies the new patent application submitted herewith. 37 CFR §1.97(a).
- (b) ☐ is filed within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491.
- (c) ☒ as far as is known to the undersigned, is filed before the mailing date of a first Office action on the merits. Should any fee be due, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$240.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account.
- (d) ☐ is filed after the first Office Action and more than three months after the application's filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and is accompanied by either the fee (\$240) set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below. Should any fee be due, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$240.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit

account. **A duplicate of this sheet is enclosed.**

- (e) ☐ is filed after the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by the fee (\$130) set forth in 37 CFR §1.17(i) and a statement as specified in 37 CFR §1.97(e), as checked below. **This document is to be considered as a petition requesting consideration of the information disclosure statement.** The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$130.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. **A duplicate of this sheet is enclosed.**

[If either of boxes (d) or (e) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.] The undersigned states that:

- ☐ Each item of information contained in the information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

A list of the patent(s) or publication(s) is set forth on the attached Form PTO-1449 (Modified).

A copy of the items on PTO-1449 is supplied herewith:

☒ each ☐ none ☐ only those listed below:

Except for the items marked with an asterisk (\*) which are not included.

☐ BLAST results enclosed:

The undersigned also wishes to bring to the attention of the Examiner BLAST results of computerized alignments of the against sequences contained in the GenBank and Dayhoff databases. The BLAST results are provided in paper form and are identified as reference "BLAST Results A-1- A-()" (GenBank) and "BLAST Results B-1 - B-()" (Dayhoff) on the PTO Form 1449. Applicant requests that these references also be considered and that the Form 1449 be initialed to indicate the Examiner's consideration of the references.

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s) [Required]

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a

counterpart application, which refers to the relevant portions of the references.

The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention," MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

GENENTECH, INC.

Date: November 3, 2000


By: 

Wendy Lee

Reg. No. 40,378

1 DNA Way  
So. San Francisco, CA 94080-4990  
Phone: (650) 225-1994  
Fax: (650) 952-9881

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1760R1	Serial No. 09/602,800
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Agus et al.	
				Filing Date 23 Jun 2000	Group 1614



U.S. PATENT DOCUMENTS							
Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date	
	1	4,968,603	06.11.90	Slamon et al.			
	2	5,183,884	02.02.93	Kraus et al.			
	3	5,480,968	02.01.96	Kraus et al.			
	4	5,641,869	24.06.97	Vandlen et al.			
	5	5,783,186	21.07.98	Arakawa et al.			
	6	5,821,337	13.10.98	Carter et al.			
	7	5,824,311	20.10.98	Greene et al.			
	8	5,882,864	16.03.99	An et al.			

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes No	
	9	599,274	01.06.94	EPO			
	10	WO 94/00136	06.01.94	PCT			
	11	WO 94/22478	13.10.94	PCT			
	12	WO 98/16628	23.04.98	PCT			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)	
13	Aasland et al., "Expression of oncogenes in thyroid tumours: Coexpression of c-erbB2/neu and c-erbB" <u>British Journal of Cancer</u> 57(4):358-363 (Apr 1988)
14	Agus et al., "Response of Prostate Cancer to Anti-Her-2/neu Antibody in Androgen-dependent and -independent Human Xenograft Models" <u>Cancer Research</u> 59:4761-4764 (1999)
15	Arteaga et al., "p185C-erbB-2 Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association Between an Oncogenic Receptor Tyrosine Kinase and Drug-induced DNA Repair" <u>Cancer Research</u> 54(14):3758-3765 (Jul 15, 1994)
16	Baca et al., "Antibody Humanization Using Monovalent Phage Display" <u>Journal of Biological Chemistry</u> 272(16):10678-10684 (1997)
17	Bacus et al., "Differentiation of Cultured Human Breast Cancer Cells (AU-565 and MCF-7) Associated With Loss of Cell Surface HER-2/neu Antigen" <u>Molecular Carcinogenesis</u> 3(6):350-362 (1990)
18	Bacus et al., "Tumor-inhibitory Monoclonal Antibodies to the HER-2/Neu Receptor Induce Differentiation of Human Breast Cancer Cells" <u>Cancer Research</u> 52(9):2580-2589 (May 1, 1992)
19	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2 Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer" <u>J. Clin. Oncol.</u> 14(3):737-744 (Mar 1996)
20	Baselga et al., "Receptor Blockade With Monoclonal Antibodies As Anti-Cancer Therapy" <u>Pharmac. Ther.</u> 64:127-154 (1994)
21	Borst et al., "Oncogene Alterations in Endometrial Carcinoma" <u>Gynecologic Oncology</u> 38(3):364-366 (Sep 1990)
22	Carraway et al., "A Neu Acquaintance for ErbB3 and ErbB4: A Role for Receptor Heterodimerization in Growth Signaling" <u>Cell</u> 78:5-8 (Jul 15, 1994)
23	Carraway et al., "Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases" <u>Nature</u> 387:512-516 (May 1997)

Examiner	Date Considered
----------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1760R1	Serial No. 09/602,800
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Agus et al.	
				Filing Date 23 Jun 2000	Group 1614
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
24	Carter et al., "Humanization of an anti-p185HER2 antibody for human cancer therapy" <u>Proc. Natl. Acad. Sci.</u> 89:4285-4289 (May 1992)				
25	Chang et al., "Ligands for ErbB-family receptors encoded by a neuregulin-like gene" <u>Nature</u> 387:509-512 (May 29, 1997)				
26	Cohen et al., "Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract" <u>Oncogene</u> 4(1):81-88 (Jan 1989)				
27	Craft et al., "A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase" <u>Nature Medicine</u> 5(3):280-285 (Mar 1999)				
28	D'souza et al., "Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene" <u>Proc. Natl. Acad. Sci. USA</u> 91(15):7202-7206 (Jul 19, 1994)				
29	Drebin et al., "Down-Modulation of an Oncogene Protein Product and Reversion of the Transformed Phenotype by Monoclonal Antibodies" <u>Cell</u> 41(3):695-706 (Jul 1985)				
30	Drebin et al., "Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo" <u>Oncogene</u> 2:273-277 (1988)				
31	Earp et al., "Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research" <u>Breast Cancer Res and Treatment</u> 35:115-132 (1995)				
32	Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product" <u>Cancer Research</u> 50:1550-1558 (Mar 1, 1990)				
33	Fukushige et al., "Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line" <u>Molecular &amp; Cellular Biology</u> 6(3):955-958 (Mar 1986)				
34	Gibson et al., "A novel method for real time quantitative RT-PCR" <u>Genome Research</u> 6(10):995-1001 (Oct 1996)				
35	Groenen et al., "Structure-Function Relationships for the EGF/TGF- $\alpha$ Family of Mitogens" <u>Growth Factors</u> 11:235-257 (1994)				
36	Gu et al., "Overexpression of her-2/neu in human prostate cancer and benign hyperplasia" <u>Cancer Lett.</u> 99:185-189 (1996)				
37	Guerin et al., "Overexpression of Either c-myc or c-erbB-2/neu Proto-Oncogenes in Human Breast Carcinomas: Correlation with Poor Prognosis" <u>Oncogene Res</u> 3:21-31 (1988)				
38	Hancock et al., "A Monoclonal Antibody against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum against Human Breast and Ovarian Tumor Cell Lines" <u>Cancer Research</u> 51:4575-4580 (Sep 1, 1991)				
39	Harari et al., "Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase" <u>Oncogene</u> 18:2681-2689 (1999)				
40	Harwerth et al., "Monoclonal Antibodies against the Extracellular Domain of the erbB-2 Receptor Function as Partial Ligand Agonists" <u>Journal of Biological Chemistry</u> 267(21):15160-15167 (Jul 25, 1992)				
41	Heid et al., "Real time quantitative PCR" <u>Genome Research</u> 6(10):986-994 (Oct 1996)				
42	Holmes et al., "Identification of Heregulin, a Specific Activator of p185erbB2" <u>Science</u> 256:1205-1210 (May 22, 1992)				
43	Hudziak et al., "Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells" <u>Proc. Natl. Acad. Sci.</u> 84(20):7159-7163 (Oct 1987)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1760R1	Serial No. 09/602,800
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Agus et al.	
				Filing Date 23 Jun 2000	Group 1614
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
44	Hudziak et al., "p185 <sup>HER2</sup> Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" <u>Molecular &amp; Cellular Biology</u> 9(3):1165-1172 (Mar 1989)				
45	Jones et al., "Binding Interaction of the Heregulin $\beta$ egf Domain with ErbB3 and ErbB4 Receptors Assessed by Alanine Scanning Mutagenesis" <u>Journal of Biological Chemistry</u> 273(19):11667-11674 (May 8, 1998)				
*46	Kabat <u>Sequences of Proteins of Immunological Interest</u> , US Dept of Health and Human Services, NIH, 5th edition, Bethesda, MD (1991)				
47	Kasprzyk et al., "Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies" <u>Cancer Research</u> 52(10):2771-2776 (May 15, 1992)				
48	Kern et al., "p185 <sup>neu</sup> Expression in Human Lung Adenocarcinomas Predicts Shortened Survival" <u>Cancer Research</u> 50(16):5184-5191 (Aug 15, 1990)				
49	King et al., "Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma" <u>Science</u> 229:974-976 (Sept 1985)				
50	Klapper et al., "A subclass of tumor inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors" <u>Oncogene</u> 14:2099-2109 (1997)				
51	Kotts et al., "Differential Growth Inhibition of Human Carcinoma Cells Exposed to Monoclonal Antibodies Directed against the Extracellular Domain of the HER2/ERBB2 Protooncogene" <u>In Vitro</u> (Abstract #176) 26(3):59A (1990)				
52	Kraus et al., "Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors" <u>Proc. Natl. Acad. Sci. USA</u> 86:9193-9197 (Dec 1989)				
53	Kumar et al., "Regulation of Phosphorylation of the c-erbB-2/HER2 Gene Product by a Monoclonal Antibody and Serum Growth Factor(s) in Human Mammary Carcinoma Cells" <u>Molecular &amp; Cellular Biology</u> 11(2):979-986 (Feb 1991)				
54	Lee et al., "Transforming Growth Factor $\alpha$ : Expression, Regulation, and Biological Activities" <u>Pharmacological Reviews</u> 47(1):51-85 (Mar 1995)				
55	Lemke, G., "Neuregulins in Development" <u>Molecular and Cellular Neuroscience</u> 7:247-262 (1996)				
56	Levi et al., "The Influence of Heregulins on Human Schwann Cell Proliferation" <u>J. Neuroscience</u> 15(2):1329-1340 (Feb 1995)				
57	Lewis et al., "Differential responses of human tumor cell lines to anti-p185 <sup>HER2</sup> monoclonal antibodies" <u>Cancer Immunol. Immunother.</u> 37:255-263 (1993)				
58	Lewis et al., "Growth Regulation of Human Breast and Ovarian Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in Mediating Heregulin Responsiveness" <u>Cancer Research</u> 56:1457-1465 (Mar 15, 1996)				
59	Maier et al., "Requirements for the Internalization of a Murine Monoclonal Antibody Directed against the HER-2/neu Gene Product c-erbB-2" <u>Cancer Research</u> 51(19):5361-5369 (Oct 1, 1991)				
60	Masui et al., "Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies" <u>Cancer Research</u> 44(3):1002-1007 (Mar 1984)				
61	McCann et al., "c-erbB-2 Oncoprotein Expression in Primary Human Tumors" <u>Cancer</u> 65(1):88-92 (Jan 1, 1990)				
62	McKenzie et al., "Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185" <u>Oncogene</u> 4:543-548 (1989)				
63	Morrissey et al., "Axon-induced mitogenesis of human Schwann cells involves heregulin and p185 <sup>erbB2</sup> " <u>Proc. Natl. Acad. Sci. USA</u> 92:1431-1435 (Feb 1995)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1760R1	Serial No. 09/602,800
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Agus et al.	
				Filing Date 23 Jun 2000	Group 1614
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
64	Myers et al., "Biological Effects of Monoclonal Antireceptor Antibodies Reactive with neu Oncogene Product, p185neu" <u>Methods in Enzymology</u> 198:277-290 (1991)				
65	Nagabhushan et al., "CWR22: The First Human Prostate Cancer Xenograft with Strongly Androgen-dependent and Relapsed Strains Both in Vivo and in Soft Agar" <u>Cancer Research</u> 56:3042-3046 (1996)				
66	Park et al., "Amplification, Overexpression, and Rearrangement of the erbB-2 Protooncogene in Primary Human Stomach Carcinomas" <u>Cancer Research</u> 49(23):6605-6609 (Dec 1, 1989)				
67	Pietras et al., "Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells" <u>Oncogene</u> 9:1829-1838 (1994)				
68	Plowman et al., "Heregulin induces tyrosine phosphorylation of HER4/p180erbB4" <u>Nature</u> (Letters to Nature) 366:473-475 (Dec 2, 1993)				
69	Plowman et al., "Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family" <u>Proc. Natl. Acad. Sci. USA</u> 90:1746-1750 (Mar 1993)				
70	Presta et al., "Humanization of an Anti Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders" <u>Cancer Research</u> 57(20):4593-4599 (Oct 15, 1997)				
71	Ross et al., "HER-2/neu Gene Amplification Status in Prostate Cancer by Fluorescence in Situ Hybridization" <u>Hum. Pathol.</u> 28(7):827-833 (July 1997)				
72	Ross et al., "Prognostic Significance of HER-2/neu Gene Amplification Status by Fluorescence In Situ Hybridization of Prostate Carcinoma" <u>Cancer</u> 79(11):2162-2170 (June 1, 1997)				
73	Sadasivan et al., "Overexpression of Her-2/Neu May Be An Indicator of Poor Prognosis in Prostate Cancer" <u>J. Urol.</u> 150:126-131 (Jul 1993)				
74	Sarup et al., "Characterization of an Anti-P185HER2 Monoclonal Antibody that Stimulates Receptor Function and Inhibits Tumor Cell Growth" <u>Growth Regulation</u> 1:72-82 (1991)				
75	Schaefer et al., "A Discrete Three-amino Acid Segment (LVI) at the C-terminal End of Kinase-impaired ErbB3 is required for Transactivation of ErbB2" <u>Journal of Biological Chemistry</u> 274(2):859-866 (Jan 8, 1999)				
76	Schaefer et al., "γ-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175" <u>Oncogene</u> 15:1385-1394 (1997)				
77	Scott et al., "p185HER2 Signal Transduction in Breast Cancer Cells" <u>Journal of Biological Chemistry</u> 266(22):14300-14305 (Aug 5, 1991)				
78	Shawver et al., "Ligand-like Effects Induced by Anti-c-erbB-2 Antibodies Do Not Correlate with and Are Not Required for Growth Inhibition of Human Carcinoma Cells" <u>Cancer Research</u> 54(5):1367-1373 (Mar 1, 1994)				
79	Shepard et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic" <u>J. Clin. Immunol.</u> 11(3):117-127 (1991)				
80	Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" <u>Science</u> 235:177-182 (Jan 9, 1987)				
81	Slamon et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer" <u>Science</u> 244:707-712 (May 12, 1989)				
82	Sliwkowski et al., "Coexpression of erbB2 and erbB3 Proteins Reconstitutes a High Affinity Receptor for Heregulin" <u>Journal of Biological Chemistry</u> 269(20):14661-14665 (May 20, 1994)				
83	Stancovski et al., "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth" <u>Proc. Natl. Acad. Sci. USA</u> 88(19):8691-8695 (Oct 1, 1991)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1760R1	Serial No. 09/602,800
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Agus et al.	
				Filing Date 23 Jun 2000	Group 1614
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
84	Stearns et al., "Workgroup 2: Human Xenograft Models of Prostate Cancer" <u>Prostate</u> 36:56-58 (1998)				
85	Sugarman et al., "Recombinant Human Tumor Necrosis Factor- $\alpha$ : Effects on Proliferation of Normal and Transformed Cells in Vitro" <u>Science</u> 230:943-945 (1985)				
86	Tagliabue et al., "Selection of monoclonal antibodies which induce internalization and phosphorylation of p185 <sup>HER2</sup> and growth inhibition of cells with HER2/NEU gene amplification" <u>International Journal of Cancer</u> 47(6):933-937 (Apr 1, 1991)				
87	Vitetta et al., "Monoclonal Antibodies as Agonists: An Expanded Role for Their Use in Cancer Therapy" <u>Cancer Research</u> 54(20):5301-5309 (Oct 15, 1994)				
88	Wainstein et al., "CWR22: Androgen-dependent Xenograft Model Derived from a Primary Human Prostatic Carcinoma" <u>Cancer Research</u> 54:6049-6052 (1994)				
89	Weiner et al., "Expression of the neu Gene-encoded Protein (P185 <sup>neu</sup> ) in Human Non-Small Cell Carcinomas of the Lung" <u>Cancer Research</u> 50(2):421-425 (Jan 15, 1990)				
90	Werther et al., "Humanization of an Anti-Lymphocyte Function-Associated Antigen (LFA)-1 Monoclonal Antibody and Reengineering of the Humanized Antibody for Binding to Rhesus LFA-1" <u>J. of Immunology</u> 157:4986-4995 (1996)				
91	Williams et al., "Expression of c-erbB-2 in Human Pancreatic Adenocarcinomas" <u>Pathobiology</u> 59(1):46-52 (1991)				
92	Wofsy et al., "Modification and Use of Antibodies to Label Cell Surface Antigens" <u>Selected Methods in Cellular Immunology</u> , Mishel and Schiigi, eds., San Francisco:WJ Freeman Co., Chapter 13, pps. 287-304 (1980)				
93	Wu et al., "Apoptosis Induced By an Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in a Human Colorectal Carcinoma Cell Line and Its Delay By Insulin" <u>Journal of Clinical Investigation</u> 95(4):1897-1905 (Apr 1995)				
94	Xu et al., "Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185" <u>International Journal of Cancer</u> 53(3):401-408 (Feb 1, 1993)				
95	Yokota et al., "Amplification of c-erbB-2 Oncogene in Human Adenocarcinomas in Vivo" <u>Lancet</u> 1(8484):765-767 (Apr 5, 1986)				
96	Yonemura et al., "Evaluation of Immunoreactivity for erbB-2 Protein as a Marker of Poor Short Term Prognosis in Gastric Cancer" <u>Cancer Research</u> 51(3):1034-1038 (Feb 1, 1991)				
97	Zhang et al., "Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that binds and activates ErbB4" <u>Proc. Natl. Acad. Sci. USA</u> 94:9562-9567 (Sep 22, 1997)				
98	Zhou et al., "Amplification and Expression of the c-erb B-2/neu Proto-Oncogene in Human Bladder Cancer" <u>Molecular Carcinogenesis</u> 3(5):254-257 (1990)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					